---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122770"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:36:58.782145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio Q3 net loss $17.6M ($1.46/sh); cash $89.1M; bempikibart Phase 2 AD and AA topline due Dec 2024

## Summary
- Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.
- Cash $89.1M expected to fund operations into mid-2026 through four Phase 2 milestones.
- Bempikibart SIGNAL-AD trial enrolled 121 patients; topline results in AD and AA both expected December 2024.
- ADX-097 Phase 2 renal basket enrollment ongoing; initial open-label data 1H’25, topline 2H’25; AAV trial to start 1H’25.
- Positive Phase 1 ADX-097 data presented at ASN Kidney Week 2024 supporting Phase 2 dose.

## SEC filing metadata
- accession: 0000950170-24-122770
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017024122770/0000950170-24-122770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017024122770/qttb-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122770
- JSON: https://secwatch.observer/filing/0000950170-24-122770.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.